Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1991-05-08
1993-02-23
Cashion, Jr., Merrell C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 15, A61K 3702
Patent
active
051890224
ABSTRACT:
The present invention relates to a method of treating chronic fatigue syndrome not associated with an HIV infection. In the method of the present invention patients are administered a pharmaceutically acceptable carrier together with
REFERENCES:
patent: 4880626 (1989-11-01), McMichael
patent: 5013739 (1991-05-01), Bihari et al.
Jordan Grafman, et al. Cognitive and Mood-State Changes in Patients with Chronic Fatigue Syndrome. vol. 13 Jan.-Feb. 1991.
James T. Becker, Methodologic Considerations in Assessment of Cognitive Function in Chronic Fatigue Syndrome vol. 13 Jan.-Feb. 1991.
Straus-Stephen-E. et al., Acyclovir Treatment of The Chronic Fatigue Syndrome: Lack of Efficacy in a Placebo-Controlled Trail.
Lloyd-Andrew et al., A Double-Blind, Placebo-Controlled Trail of Intravenous Immunoglobulin Therapy in Patients with Chronic Fatigue Syndrome. The American Journal of Medicine, Nov. 1990 89(5), pp. 561-568.
Peterson-Phillip-K. et al., A Controlled Trail of Intravenous Immunoglobulin G in Chronic Fatigue Syndrome. The American Journal of Medicine. 1990 No. 89 (5). pp. 554-560.
Linde, R. et al., Sixth Int'l Conference of AIDS, vol. 75 1-3, Abs. 2183, 1990.
Bridge Thomas P.
Goodwin Frederick K.
Cashion Jr. Merrell C.
Perkins Susan M.
The United States of America as represented by the Secretary of
LandOfFree
Composition for the treatment of chronic fatigue syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for the treatment of chronic fatigue syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for the treatment of chronic fatigue syndrome will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2204926